Organization
Roche Products Limited
7 abstracts
Abstract
Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis.Org: Gregorio Marañón University General Hospital, IRCCS Istituto Romagnolo per lo Studio dei Tumori, Institute of Oncology Ljubljana, Roche Products Limited, Roche,
Abstract
First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2‑negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses.Org: Roche Products Ltd., Genentech, Roche Products Limited, German Breast Group, Centre for Haematology and Oncology Bethanien,
Abstract
IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care.Org: Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, LungenClinic, Grosshansdorf, Germany, German Center of Lung Research, Genentech Inc., Stanford University School of Medicine/Stanford Cancer Institute,
Abstract
INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) PIK3CA‑mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Winship Cancer Center of Emory University, Seoul National University Hospital, Cancer Research Institute,
Abstract
A disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2+ unresectable locally advanced or metastatic breast cancer (aBC): Interim results of the ESTHER study (NCT02393924).Org: Roche Products Limited, Cmed Clinical Research Services, Leeds Institute of Medical Research at St James’s, Kent Oncology Centre, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research,
Abstract
A UK COST-EFFECTIVENESS ANALYSIS ON THE USE OF TOCILIZUMAB (ROACTEMRA®) WITH METHOTREXATE IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS WHO HAVE FAILED TO RESPOND ADEQUATELY TO ONE OR MORE DMARDS Org: Healthcare Management, Roche Products Limited, Genentech, THEMA Research Ltd,
Abstract
AN ECONOMIC EVALUATION ON THE USE OF TOCILIZUMAB (ROACTEMRA®) WITH METHOTREXATE IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS WHO HAVE FAILED TO RESPOND ADEQUATELY TO AN ANTI-TNF DRUG IN SCOTLAND Org: Healthcare Management, Roche Products Limited, Global Health Economics and Pricing, Genentech, THEMA Research Ltd,